Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.
Dyno Therapeutics, a US-based gene therapy spinout of Harvard University, completed a $100m series A round yesterday that included GV, a corporate venturing subsidiary of internet and technology group Alphabet.
Venture capital firm Andreessen Horowitz led the round, which also featured life sciences investment firm Casdin Capital and VC firms Obvious Ventures, Lux Capital, CRV and KdT Ventures as well as investment firm Polaris Partners.
Dyno’s CapsidMap platform optimises adeno-associated virus capsid vectors, applying artificial intelligence and machine…
